Selected recent trials evaluating cardiovascular events in patients treated for Hodgkin’s lymphoma.
| . | . | . | . | No. of Pts. with Cardiovascular Events . | Relative Risk# . | Absolute Excess Risk‡ . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author . | Years of Accrual . | No. of Treated Patients . | Range of Follow-up . | Cardiac . | Non- Cardiac . | Valvular . | Cardiac . | Non- Cardiac . | Valvular . | Cardiac . | Non- Cardiac . | Valvular . |
| # Relative risk refers to the ratio of observed vs. expected events | ||||||||||||
| ‡ Absolute excess risk refers to the number of observed events minus expected events per 10,000 patient-years of follow-up | ||||||||||||
| * refers to number of surgical interventions performed in comparison with a matched control population | ||||||||||||
| ** refers to fatal cardiac ischemic events | ||||||||||||
| *** refers to myocardial infarction; 31 other patients had other cardiac events; 16 deaths (25% of all deaths) were attributed to a cardiovascular event | ||||||||||||
| **** refers to stroke, transient ischemic attack or carotid artery narrowing | ||||||||||||
| Abbreviations: ns, not stated | ||||||||||||
| Hull22 | 1962–1998 | 415 | 2.1–36.3 yrs (median 11.2 yrs) | 42 | 30 | 25 | 1.63* | ns | 8.42* | ns | ns | ns |
| Reinders23 | 1965–1980 | 258 | 0.7–26.2 yrs (median 14.2 yrs) | 31 | ns | ns | 5.3** | ns | ns | 281** | ns | ns |
| Eriksson24 | 1972–1985 | 157 | 10–23 yrs (median 16 yrs) | 13** | ns | ns | 5.0** | ns | ns | 51** | ns | ns |
| Lee25 | 1970–1986 | 210 | 0.35–26.5 yrs (median 15.6 yrs) | 28*** | 16**** | ns | ns | ns | ns | ns | ns | ns |
| . | . | . | . | No. of Pts. with Cardiovascular Events . | Relative Risk# . | Absolute Excess Risk‡ . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author . | Years of Accrual . | No. of Treated Patients . | Range of Follow-up . | Cardiac . | Non- Cardiac . | Valvular . | Cardiac . | Non- Cardiac . | Valvular . | Cardiac . | Non- Cardiac . | Valvular . |
| # Relative risk refers to the ratio of observed vs. expected events | ||||||||||||
| ‡ Absolute excess risk refers to the number of observed events minus expected events per 10,000 patient-years of follow-up | ||||||||||||
| * refers to number of surgical interventions performed in comparison with a matched control population | ||||||||||||
| ** refers to fatal cardiac ischemic events | ||||||||||||
| *** refers to myocardial infarction; 31 other patients had other cardiac events; 16 deaths (25% of all deaths) were attributed to a cardiovascular event | ||||||||||||
| **** refers to stroke, transient ischemic attack or carotid artery narrowing | ||||||||||||
| Abbreviations: ns, not stated | ||||||||||||
| Hull22 | 1962–1998 | 415 | 2.1–36.3 yrs (median 11.2 yrs) | 42 | 30 | 25 | 1.63* | ns | 8.42* | ns | ns | ns |
| Reinders23 | 1965–1980 | 258 | 0.7–26.2 yrs (median 14.2 yrs) | 31 | ns | ns | 5.3** | ns | ns | 281** | ns | ns |
| Eriksson24 | 1972–1985 | 157 | 10–23 yrs (median 16 yrs) | 13** | ns | ns | 5.0** | ns | ns | 51** | ns | ns |
| Lee25 | 1970–1986 | 210 | 0.35–26.5 yrs (median 15.6 yrs) | 28*** | 16**** | ns | ns | ns | ns | ns | ns | ns |